Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.45 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.45 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.42 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.42 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.42 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14372548 | 0.77 | SMN1; SMN2 (0.60) | HTR2CSMN1; SMN2NPC1RAB9ACACNA1G | |
| SCHEMBL2980232 | 0.76 | HTR2C (0.43) | HTR2CALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL5517082 | 0.75 | HTR2C (0.64) | HTR2CSMN1; SMN2NPC1RAB9ACACNA1G | |
| SCHEMBL10053573 | 0.75 | HTR2C (0.64) | HTR2CSMN1; SMN2NPC1RAB9ACACNA1G | |
| SCHEMBL5517077 | 0.75 | HTR2C (0.64) | HTR2CSMN1; SMN2NPC1RAB9ACACNA1G | |
| SCHEMBL6819973 | 0.75 | SMN1; SMN2 (0.48) | HTR2CSMN1; SMN2NPC1RAB9ACACNA1G | |
| SCHEMBL8562576 | 0.74 | KMT2A (0.48) | HTR2CSMN1; SMN2NPC1RAB9ACACNA1G | |
| SCHEMBL16472423 | 0.74 | SMN1; SMN2 (0.60) | HTR2CSMN1; SMN2NPC1RAB9ACACNA1G | |
| SCHEMBL15218647 | 0.74 | SMN1; SMN2 (0.60) | HTR2CSMN1; SMN2NPC1RAB9ACACNA1G | |
| SCHEMBL19942091 | 0.74 | HTR2C (0.46) | HTR2CSMN1; SMN2NPC1RAB9ACACNA1G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130072470-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC. (US) | 2013-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072470-A1 | NOVEL TRICYCLIC COMPOUNDS | CYP11B2, CYP11B1, ABCB1 | HTR2C 1556/4885SMN1; SMN2 3229/4885NPC1 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.